{"nctId":"NCT00313313","briefTitle":"A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas","startDateStruct":{"date":"2006-04"},"conditions":["Diabetes"],"count":768,"armGroups":[{"label":"Saxagliptin 2.5 mg + Glyburide 7.5 mg (A)","type":"EXPERIMENTAL","interventionNames":["Drug: Saxagliptin","Drug: Glyburide","Drug: Metformin"]},{"label":"Saxagliptin 5 mg + Glyburide 7.5 mg (B)","type":"EXPERIMENTAL","interventionNames":["Drug: Saxagliptin","Drug: Glyburide","Drug: Metformin"]},{"label":"Placebo + Glyburide 7.5 mg (C)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo","Drug: Glyburide","Drug: Metformin"]}],"interventions":[{"name":"Saxagliptin","otherNames":["BMS-477118"]},{"name":"Saxagliptin","otherNames":["BMS-477118"]},{"name":"Glyburide","otherNames":[]},{"name":"Placebo","otherNames":[]},{"name":"Glyburide","otherNames":[]},{"name":"Metformin","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Type 2 Diabetes.\n* Treated with a sulfonylurea for at least 2 months.\n* Inadequate blood sugar control.\n* Are not on any other medications to lower blood sugar.\n* No major heart, liver or kidney problems.\n* Women not pregnant or breast feeding.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"77 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Hemoglobin A1c (A1C) at Week 24","description":"Mean change from baseline in A1C at Week 24, adjusted for baseline value.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.36","spread":"0.057"},{"groupId":"OG001","value":"8.48","spread":"0.056"},{"groupId":"OG002","value":"8.44","spread":"0.055"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.83","spread":"0.074"},{"groupId":"OG001","value":"7.83","spread":"0.074"},{"groupId":"OG002","value":"8.52","spread":"0.077"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.54","spread":"0.059"},{"groupId":"OG001","value":"-0.64","spread":"0.059"},{"groupId":"OG002","value":"0.08","spread":"0.057"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24","description":"Mean change from baseline in FPG at Week 24, adjusted for baseline value.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"170.1","spread":"2.67"},{"groupId":"OG001","value":"175.0","spread":"2.79"},{"groupId":"OG002","value":"174.4","spread":"2.64"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"164.4","spread":"2.76"},{"groupId":"OG001","value":"164.6","spread":"2.76"},{"groupId":"OG002","value":"174.6","spread":"2.93"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-7.1","spread":"2.42"},{"groupId":"OG001","value":"-9.7","spread":"2.39"},{"groupId":"OG002","value":"0.7","spread":"2.33"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving A1C < 7% at Week 24","description":"Percentage of participants achieving A1C \\< 7%, the American Diabetes Association's defined goal for glycemia, at each dose of saxagliptin plus glyburide versus placebo plus upward titrated glyburide at Week 24.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"22.4","spread":null},{"groupId":"OG001","value":"22.8","spread":null},{"groupId":"OG002","value":"9.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Changes From Baseline in Postprandial Glucose (PPG) Area Under the Curve (AUC) Response to an Oral Glucose Tolerance Test (OGTT) at Week 24","description":"Mean change from baseline for 0 to 180 minutes PPG AUC at Week 24, adjusted for baseline values.","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49124","spread":"677.2"},{"groupId":"OG001","value":"50342","spread":"669.0"},{"groupId":"OG002","value":"51801","spread":"656.9"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"45402","spread":"681.5"},{"groupId":"OG001","value":"45391","spread":"699.3"},{"groupId":"OG002","value":"52416","spread":"703.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-4296","spread":"595.0"},{"groupId":"OG001","value":"-5000","spread":"585.5"},{"groupId":"OG002","value":"1196","spread":"574.5"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":23,"n":267},"commonTop":["URINARY TRACT INFECTION","NASOPHARYNGITIS","HEADACHE","INFLUENZA","UPPER RESPIRATORY TRACT INFECTION"]}}}